Your session is about to expire
← Back to Search
Other
CBDRA60 supplement for COVID-19
N/A
Waitlist Available
Led By Eleni Stylianou, PHD
Research Sponsored by Anewsha Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
The study population will include individuals who tested positive for COVID-19 infection based on a PCR test. The study population is defined as adults ≥ 18 years of age with no comorbidities and absence of pre-existing conditions (see
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 35 days
Awards & highlights
Study Summary
This trial is testing a supplement, CBDRA60, that is a combination of cannabidiol and gigartina red algae, to see if it can help reduce the duration of symptoms in patients with COVID-19.
Eligible Conditions
- COVID-19
- Coronavirus
- Hay Fever
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 35 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~35 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Decreased hospitalization
Secondary outcome measures
Resolution of COVID-19 symptoms
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: CBDRA60 supplementExperimental Treatment1 Intervention
Daily sublingual tablet containing 30mg Cannabidiol and 30mg Red Algae, a total of 60mg per dose. Participants will take 2 tablets per day, sublingually and with food, taken approximately and at least, 8 hours apart, daily for 28 days. Participants will be mailed a supply of pills by an overnight courier service.
Group II: PlaceboPlacebo Group1 Intervention
Control subjects will receive daily oral placebo tablets of identical appearance and taste containing no CBDRA60.
Find a Location
Who is running the clinical trial?
Anewsha Therapeutics Inc.Lead Sponsor
University of MichiganOTHER
1,796 Previous Clinical Trials
6,377,896 Total Patients Enrolled
21 Trials studying COVID-19
20,124 Patients Enrolled for COVID-19
Biologics ConsultingUNKNOWN
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment for this experiment still open?
"This clinical trial is not currently recruiting candidates, according to the information hosted on clinicaltrials.gov. The post was initially published on July 1st 2022 and last edited on February 18th of the same year. Despite this inactivity, 1737 other trials are actively accepting patients at present time."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger